Vericiguat

Vericiguat, sold as Verquvo, is a soluble guanylate cyclase stimulator, a medicine taken by mouth. The US label read lists one use in adults: to reduce the risk of cardiovascular death and hospitalization for heart failure after a hospitalization for heart failure or the need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction below 45%. The label carries a boxed warning for embryo-fetal toxicity, which concerns the unborn child and is recorded separately.

Also called Verquvo

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 2475830; UNII LV66ADM269. MeSH has no descriptor for vericiguat (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Soluble Guanylate Cyclase Stimulator. The record is filed under the class page for soluble guanylate cyclase stimulators on that evidence. The label read is the Merck Sharp & Dohme LLC label for Verquvo, application NDA214377, effective 2026-01-21 in openFDA. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the title and one sentence of the boxed warning, the mechanism sentence and the class only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says vericiguat stimulates soluble guanylate cyclase, an enzyme in the nitric oxide signaling pathway.

Claims and evidence

Context Adults with symptomatic chronic heart failure and an ejection fraction below 45%, as described in the US label of Verquvo

Recipient
Adult
Population
Adults with symptomatic chronic heart failure and an ejection fraction less than 45%, following a hospitalization for heart failure or the need for outpatient intravenous diuretics, as the label states.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the label states
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Adults with symptomatic chronic heart failure and ejection fraction less than 45%
  • Following a hospitalization for heart failure or need for outpatient intravenous diuretics
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Verquvo (vericiguat tablets, Merck Sharp & Dohme LLC, application NDA214377; the version dated 2026-01-21 in openFDA) describes vericiguat as a soluble guanylate cyclase stimulator. It lists reducing the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and an ejection fraction less than 45%.

    Applies to Adult Adults with symptomatic chronic heart failure and an ejection fraction below 45%, as described in the US label of Verquvo

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The boxed warning is in a separate claim about the fetus. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, second sentence
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (LB-05, LB-06).
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260121.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning

Recipient
Fetal
Population
The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Fetus during pregnancy; the passage read gives no gestational ages
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Pregnancy during which the medicine is taken (risk to the fetus)
Excluded
None stated
  • Safety Evidence stage not applicable Certainty not assessed

    The same US label of Verquvo carries a boxed warning titled embryo-fetal toxicity. It says the medicine may cause fetal harm.

    Applies to Fetal The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning

    Certainty method
    Not assessed
    Limitations
    This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0], title
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0], first paragraph
      How it applies
      Label passage quoted in the research quote table (LB-08).
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260121.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In pregnancy 1

Claims whose context is a pregnancy or a fetus.

  • Safety Evidence stage not applicable Certainty not assessed

    The same US label of Verquvo carries a boxed warning titled embryo-fetal toxicity. It says the medicine may cause fetal harm.

    Applies to Fetal The developing fetus, for a person taking vericiguat during pregnancy, as described in a US label boxed warning

    Population, setting and follow-up
    • The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Fetus during pregnancy; the passage read gives no gestational ages
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0], title
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0], first paragraph
      How it applies
      Label passage quoted in the research quote table (LB-08).
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Verquvo (vericiguat tablets), Merck Sharp & Dohme LLC label: indications, mechanism, class and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d (manufacturer Merck Sharp & Dohme LLC, application NDA214377), returned on 2026-11-18. The label text is dated 2026-01-21 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260121.
      Retrieved
      Source effective date
      2026-01-21
      Source state
      Current
      Version fingerprint
      efbd1ec7abe119bed32a485edf9b1c38a18ae0d0dd523ed13a7e4ea37cf954eb
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:vericiguat
Content hash
c94c5f6dba6a2a04cc230cfb0dc7e3800a84311a848d2060d0b3f04fbf69fab8